Clinical trial
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of…
NCT04222972 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT04222972 |
|---|---|
| Title | A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) |
| Official title | A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer |
| Acronym | AcceleRET-Lung |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Diseases, Respiratory Tract Disease and 7 more |
| Intervention type | Drug |
| Interventions | Pralsetinib, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab, Gemcitabine, Paclitaxel, Nab-Paclitaxel |
| Enrollment | 223 |
| Start date | Jul 24, 2020 |
| Primary completion | Jan 27, 2025 |
| Completion | Jan 27, 2025 |
| First posted | Jan 10, 2020 |
| Last update posted | Feb 6, 2025 |
| Countries | Argentina, Australia, Belgium, Brazil, Costa Rica, France, Germany, Ireland, Italy, Japan, Mexico, Netherlands and 9 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: